Biocon’s arm receives USFDA’s approval for Daptomycin injection

02 Sep 2024 Evaluate

Biocon’s wholly owned subsidiary -- Biocon Pharma has received approval of its ANDA for Daptomycin for injection (500mg vial), from the U.S Food and Drug Administration (USFDA). This product is indicated for use in the treatment of complicated skin and skin structure infections (cSSSI). 

It is also used to treat Staphylococcus aureus infections in the bloodstream (bacteremia), including right-sided infective endocarditis in adult patients. The approval further adds to Biocon’s portfolio of complex drug products.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

398.05 -3.35 (-0.83%)
24-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1737.50
Dr. Reddys Lab 1266.35
Cipla 1496.35
Zydus Lifesciences 917.45
Lupin 2109.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×